Repare Therapeutics Inc. (NASDAQ:RPTX) Short Interest Update

Repare Therapeutics Inc. (NASDAQ:RPTX) was the recipient of a large decline in short interest in December. As of December 31st, there was short interest totaling 194,336 shares, a decline of 44.8% from the December 15th total of 352,361 shares. Based on an average daily trading volume, of 1,759,426 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.5% of the company’s stock are short sold. Approximately 0.5% of the company’s stock are short sold. Based on an average daily trading volume, of 1,759,426 shares, the days-to-cover ratio is currently 0.1 days.

Repare Therapeutics Trading Up 0.4%

RPTX stock opened at $2.58 on Friday. Repare Therapeutics has a 1-year low of $0.89 and a 1-year high of $2.66. The business’s 50 day simple moving average is $2.27 and its 200 day simple moving average is $1.87. The firm has a market capitalization of $111.22 million, a PE ratio of -1.53 and a beta of 0.97.

Repare Therapeutics (NASDAQ:RPTX) last announced its quarterly earnings results on Friday, November 14th. The company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.43. The business had revenue of $11.62 million for the quarter, compared to analyst estimates of $7.50 million. As a group, sell-side analysts predict that Repare Therapeutics will post -2.04 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. Wall Street Zen raised Repare Therapeutics to a “hold” rating in a research report on Saturday, November 15th. TD Cowen downgraded Repare Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 17th. HC Wainwright lowered their price target on Repare Therapeutics from $5.00 to $3.00 and set a “buy” rating on the stock in a research report on Monday, October 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of Repare Therapeutics in a report on Monday, December 22nd. Finally, Cowen downgraded shares of Repare Therapeutics to a “hold” rating in a report on Monday, November 17th. One equities research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Repare Therapeutics presently has an average rating of “Hold” and a consensus target price of $3.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of RPTX. Acadian Asset Management LLC raised its holdings in Repare Therapeutics by 35.6% in the 1st quarter. Acadian Asset Management LLC now owns 640,332 shares of the company’s stock valued at $624,000 after acquiring an additional 168,230 shares during the period. Quinn Opportunity Partners LLC acquired a new position in shares of Repare Therapeutics in the second quarter valued at approximately $56,000. XTX Topco Ltd bought a new position in shares of Repare Therapeutics during the second quarter worth approximately $60,000. Militia Capital Partners LP acquired a new stake in Repare Therapeutics during the 2nd quarter worth approximately $166,000. Finally, Rangeley Capital LLC bought a new stake in Repare Therapeutics in the 2nd quarter valued at $494,000. Institutional investors and hedge funds own 85.09% of the company’s stock.

Repare Therapeutics Company Profile

Repare Therapeutics, traded on NASDAQ under the symbol RPTX, is a clinical-stage biopharmaceutical company focused on the discovery and development of precision oncology medicines. The company applies synthetic lethality—a concept whereby cancer-specific genetic vulnerabilities are exploited—to design small-molecule therapies that selectively kill tumor cells while sparing healthy tissue. Repare’s proprietary functional genomics and screening platform integrates CRISPR-based assays and computational biology to systematically uncover novel genetic interactions and therapeutic targets.

At the core of Repare’s approach is its ability to identify and validate DNA damage response (DDR)-related targets.